The financial, physical, and social burdens of atopic dermatitis can be substantial, especially for patients who had the condition as children into adulthood, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.
The financial, physical, and social burdens of atopic dermatitis can be substantial, especially for patients who had the condition as children into adulthood, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.
Transcript
What is the overall burden of atopic dermatitis in the United States? What is the prevalence among the population?
So atopic dermatitis has a large burden on patients and society in this country. It’s estimated that about 31 million people or so have atopic dermatitis—7 point something percent of the population. A little bit more than those who have psoriasis. Ten million of those approximately are children, and the rest of the rest of our adults.
It really hasn't been recognized until recently that there is an entity of adult-onset atopic dermatitis. Traditionally, we thought that it was a disease of children, many of whom grew out of it as they got older—and that is true for many—but many of those children don't and many adults develop atopic dermatitis for the first time.
Financial burdens for society is great. It’s estimated, the last numbers, over about $5 billion a year in costs for payments and medical procedures for atopic dermatitis.
What is the long-term burden like for children who have atopic dermatitis that continues into adulthood?
Well, in those patients who have atopic dermatitis as lifelong disease, as children, their burden is decreased performance at school. Their burden is family burden. When a child doesn't sleep, nobody sleeps. And then that burden may continue itself through life where constant itching and scratching leading to secondary infection and poor quality of life as well as difficulty with employment can be a lifelong issue.
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS
April 11th 2025Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
April 8th 2025Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).
Read More